Patent US5567414A successfully refreshed from Google Patents.
US5567414A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Stable microbubbles suspensions injectable into living organisms
Assignee: Bracco International BV
•
Filing: 1995-06-01
•
Granted: 1996-10-22
•
Expires: 2015-06-01
Abstract
Abstract Gas or air filled microbubble suspensions in aqueous phases usable as imaging contrast agents in ultrasonic echography. They contain laminarized surfactants and, optionally, hydrophillc stabilizers. The laminarized surfactants can be in the form of liposomes. The suspensions are obtained by exposing the laminarized surfactants to air or a gas before or after admixing with an aqueous phase.
Inventors
- 👤 Michel Schneider
- 👤 Daniel Bichon
- 👤 Philippe Bussat
- 👤 Jerome Puginier
- 👤 Eva Hybl-Sutherland
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-07 19:08
CPC Classifications
A; A61; A61K; A61K49/00; A61K49/22; A61K49/222; A61K49/223; A61K49/227
Claims Analysis
Total Claims: 14
Claim 1
Independent Claim
73 words
A method of imaging organs in a living body, said method comprising administering to said body a composition consisting of a suspension of air or gas microbubbles in a physiologically acceptable aqueous carrier phase the suspension comprising one or more dissolved or dispersed surfactants, at least one of which is a film forming surfactant present in the composition at least partially in lamellar or laminar form; and subjecting said body to ultrasonic echography.
Claim 2
Independent Claim
73 words
A method of imaging organs in a living body, said method comprising administering to said body a composition consisting of a suspension of air or gas microbubbles in a physiologically acceptable aqueous carrier phase the suspension comprising one or more dissolved or dispersed surfactants, at least one of which is a film forming surfactant present in the composition at least partially in lamellar or laminar form; and subjecting said body to ultrasonic echography.
Claim 3
Dependent Claim
13 words
A method according to claim 1, wherein said suspension is administered by injection.
Claim 4
Dependent Claim
46 words
A method according to claim 2, wherein 0.1 to 2 ml of the suspension containing 10 7 -10 11 microbubbles/ml, is injected into a peripheral vein thereby providing opacification of the left heart under echographic measurements, the microbubbles being in the size range from 0.5-10 μm.
Claim 5
Dependent Claim
30 words
A method according to claim 1, wherein the film forming surfactant is a phospholipid selected from the group consisting of phosphatidic acid, phosphatidylcholine, phosphatidylethanolamine, phosphatidylserine, phosphatidylglycerol, phosphatidylinositol, cardiolipin and sphingomyelin.
Claim 6
Dependent Claim
32 words
A method according to claim 1, wherein the composition further comprises substances selected from the group consisting of dicetyl-phosphate, cholesterol, ergosterol, phytosterol, sitosterol, lanosterol, tocopterol, propyl gallate, ascorbyl palmitate and butylated hydroxytoluene.
Claim 7
Dependent Claim
32 words
A method according to claim 4, wherein the suspension further comprises viscosity enhancers or hydrosoluble stabilizers selected from the group consisting of linear and cross-linked poly- and oligo-sacchrides, sugars and hydrophilic polymers.
Claim 8
Dependent Claim
24 words
A method according to claim 6, wherein the hydrosoluble stabilizers are present in a weight ratio to the surfactants between about 1:5 and 100:1.
Claim 9
Independent Claim
36 words
A method according 1, wherein the surfactants comprise up to 50% by weight of non-laminar surfactants selected from the group consisting of fatty acids, esters and ethers of fatty acids, alcohols with polyols and polyalkylenated glycerol.
Claim 10
Independent Claim
36 words
A method according 1, wherein the surfactants comprise up to 50% by weight of non-laminar surfactants selected from the group consisting of fatty acids, esters and ethers of fatty acids, alcohols with polyols and polyalkylenated glycerol.
Claim 11
Dependent Claim
16 words
A method according to claim 8, wherein the surfactants comprise polyalkylene glycols and poly alkylenated sugars.
Claim 12
Dependent Claim
13 words
A method according to claim 1, wherein the composition comprises freeze dried liposomes.
Claim 13
Dependent Claim
42 words
A method of transporting in the bloodstream or body cavities of a host bubbles of a foreign gas active therapeutically or diagnostically, said method comprising the step of administering to said host a suspension of a formulation as defined in claim 1.
Claim 14
Dependent Claim
13 words
A method according to claim 1, wherein said composition is administered by injection.
References Cited (Backward Citations)
US4370349A
Cited
US4224179A
Cited
US4229360A
Cited
US4229360B1
Cited
US4192859A
Cited
US4276885A
Cited
US4265251A
Cited
EP0052575A2
Cited
EP0077752A2
Cited
US4466442A
Cited
GB2135647A
Cited
GB2134869A
Cited
EP0123235A2
Cited
US4900540A
Cited
EP0131540A2
Cited
US5283067A
Cited
US5089181A
Cited
WO1988007365A2
Cited
WO1988009165A1
Cited
EP0320433A2
Cited
EP0324938B1
Cited
US5088499A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1999-10-22 | 2000-04-22 | 2000-10-22 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2003-10-22 | 2004-04-22 | 2004-10-22 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2007-10-22 | 2008-04-22 | 2008-10-22 | $7700.00 | Window Closed / Lapsed |